Comparison of the efficacy of Rosa damascena extract and mefenamic acid on the severity of the primary dysmenorrhea pain

Comparison of the efficacy of Rosa damascena extract and mefenamic acid on the severity of the primary dysmenorrhea pain: A double – blind randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207267618N2

Enrollment

Registered

2012-09-16

Start date

2012-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary dysmenorrhea. Primary dysmenorrhea

Interventions

Intervention 1: Intervention group:oral capsules containing 200 mg of Rosa damascena extract every 6 hours for the first 3 days of menstruation. Intervention 2: Control group: Oral capsules containing

Treatment - Drugs

Intervention group:oral capsules containing 200 mg of Rosa damascena extract every 6 hours for the first 3 days of menstruation.

Control group: Oral capsules containing 250 mg of mefenamic acid every 6 hours for the first 3 days of menstruation

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: women with abdominal pain compatible with dysmenorrhea; being single; signing the informed consent sheet. Exclusion criteria: pain severity more than 8 or less than 5 according to visual analogue scale system; history of genitourinary disease or abdomino-pelvic surgery; stressful event(loss); lack of compliancy; history of hypersensitivity to mefenamic acid; using drugs that interact with mefenamic acid.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of dysmenorrhea pain. Timepoint: before the first intervention, after the first intervention, before the second intervention, after the second intervention. Method of measurement: visual analogue scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab alsadat Moosavi

Tabriz University of Medical Sience

zeimous_hk@yahoo.com+98 41 1479 6770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026